Clinical Study

Epigenetic Signature Of Prenatal Opioid Exposure

Posted Date: Dec 14, 2020

  • Investigator: Brittany Smith
  • Specialties:
  • Type of Study: Observational/Survey

The epigenome is highly sensitive to changes in prenatal environment. Prenatal opioid exposure causes lasting cognitive deficits in the children, so identifying biomarkers of exposure, potential risk factors, and molecular mediators for these effects will improve care and outcomes for these children. Salivary DNA methylation patterns are comparable to brain methylation patterns, so salivary DNA obtained by buccal swab represents a noninvasive means to begin to understand how opiates affect the infant brain. With prenatal opioid exposure, previous studies have shown differences in DNA methylation of specific genes, although no studies have assessed methylation on a near-genome wide scale. This study will assess DNA methylation via EPIC array in infants exposed prenatally to opiates versus non drug exposed infants. DNA will be collected at 0-1 month of age via buccal swab.


Infants 0-1 Month Of Age Exposed Prenatally To Opiates And Non-Drug Exposed Controls.


Opioids, Prenatal, Epigenetics

For More Information:

Brittany Smith

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.